First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies

Category Primary study
JournalBlood
Year 2022
This article has no abstract
Epistemonikos ID: cea43598d8dac0f74ded6c0dc2268c4b76473cb0
First added on: Feb 16, 2025